|
| Primary information |
|---|
| ID | 16286 |
| Therapeutic ID | Th1796 |
| Protein Name | Equine Botulinum Neurotoxin A Immune FAB2 |
| Sequence | NA
|
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Equine Botulinum Neurotoxin A Immune FAB2 was observed to have a mean half life of 8.64 h after administration of one vial and 10.20 h after two vials [FDA Label]. |
| Description | Equine Botulinum Neurotoxin A Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype A. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients. |
| Indication/Disease | Equine Botulinum Neurotoxin A Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype A in adults and pediatric patients [FDA Label]. |
| Pharmacodynamics | Equine Botulinum Neurotoxin A Immune FAB2 binds to botulinum toxin serotype A to prevent toxicity [FDA Label]. |
| Mechanism of Action | Equine Botulinum Neurotoxin A Immune FAB2 is a mix of polyclonal antibodies for [DB00083] [FDA Label]. It binds to the toxin with high-affinity and prevents binding to ganglioside anchorage sites and membrane-bound receptors on cholinergic nerve terminals. This prevents internalization of the toxin into the cell and ultimately prevents it from exerting its toxic effects. Due to the long-lasting effects of botulinum toxin, the antibodies must be administered before symptoms present to prevent toxicity. |
| Toxicity | Equine Botulinum Neurotoxin A Immune FAB2 may produce anapylaxis or anaphylactoid reactions particularly in patients who have previously been exposed to equine-derived antivenom or antitoxins or patient with prexisting hypersensitivity to horses, asthma, or hay fever [FDA Label]. Serum sickness reactions may present 10-21 days after infusion. Various infusion reactions may occur dependent on the rate of infusion. These include chills, fever, headaches, nausea, and vomiting. Arthralgia, myalgia, and vasovagal reactions may also occur independently of infusion rate. Because the antibodies are derived from equine plasma there is a risk of infectious disease transmission although this is controlled through manufacturing processes. |
| Metabolism | There is no metabolism data available. Equine Botulinum Neurotoxin A Immune FAB2 is assumed to be broken down similarly to other proteins and antibodies in systemic circulation. |
| Absorption | Administration of one vial of containing at least 4500 Units produced a mean Cmax of 2.69 Units/mL. Administration of two vials produced a mean Cmax of 6.23 Units/mL [FDA Label]. |
| Equine Botulinum Neurotoxin A Immune FAB2 was found to have a mean Vd of 3.637 L after administration of one vial and 3.993 L after two vials [FDA Label]. |
| Clearance | Equine Botulinum Neurotoxin A Immune FAB2 was observed to have a mean clearance rate of 293 mL/h after administration of one vial and 285 mL/h after two. |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Botulinum neurotoxin type A |
| Brand Name | Bat |
| Company | Emergent BioSolutions Canada Inc. |
| Brand Description | Emergent BioSolutions Canada Inc. |
| Prescribed For | Intravenous |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |